Quantoom Biosciences SA
Quantoom Biosciences develops integrated technologies and services to support design, production and formulation of mRNA and self-amplifying RNA (saRNA) vaccines and therapeutics. Its portfolio includes a bioinformatics RNA design platform, enzymatic linear DNA amplification services, formulation chemistry for lipid nanoparticle delivery, and automated, scalable mRNA production systems with single-step purification and process-intensification approaches. The company publishes case studies, white papers and webinars and collaborates with academic and industry partners on pre-clinical and scale-up projects.
Industries
N/A
Nr. of Employees
small (1-50)
Products
All-in-one mRNA production kit (research)
A compact kit intended to support rapid and scalable mRNA production workflows for research purposes, including reagents and disposables.
Automated mRNA production system for pre-clinical development
Bench-to-pilot automated production equipment designed for pre-clinical and drug-discovery workflows, implementing an optimized IVT and a single purification step.
Automated mRNA production system for clinical and commercial manufacturing
Larger-scale automated production system that scales by parallel reaction cavities and is intended to support clinical trials and commercial manufacturing.
All-in-one mRNA production kit (research)
A compact kit intended to support rapid and scalable mRNA production workflows for research purposes, including reagents and disposables.
Automated mRNA production system for pre-clinical development
Bench-to-pilot automated production equipment designed for pre-clinical and drug-discovery workflows, implementing an optimized IVT and a single purification step.
Automated mRNA production system for clinical and commercial manufacturing
Larger-scale automated production system that scales by parallel reaction cavities and is intended to support clinical trials and commercial manufacturing.
Services
Platform-driven design of optimised mRNA constructs from amino-acid or antigen sequences for research and development programs.
Enzymatic amplification of linear DNA templates (2–20 kb) at scales suitable for research through production, available in research and high-quality grades for downstream use.
Formulation chemistry and process development for LNP-based delivery of (sa)mRNA for vaccines and therapeutics.
Platform-driven design of optimised mRNA constructs from amino-acid or antigen sequences for research and development programs.
Enzymatic amplification of linear DNA templates (2–20 kb) at scales suitable for research through production, available in research and high-quality grades for downstream use.
Formulation chemistry and process development for LNP-based delivery of (sa)mRNA for vaccines and therapeutics.
Expertise Areas
- mRNA and self-amplifying RNA (saRNA) process development
- Bioinformatics-driven RNA design
- Lipid nanoparticle (LNP) formulation and delivery chemistry
- Automated and scalable mRNA manufacturing
Key Technologies
- mRNA and self-amplifying RNA (saRNA)
- In vitro transcription (IVT)
- Co-transcriptional mRNA capping
- Silica/magnetic-bead RNA capture purification
News & Updates
Research license and supply agreement to provide mRNA formulation technology for personalized cancer therapeutics.
Announcement of a collaboration demonstrating saRNA-based poultry vaccine outcomes using the company's integrated toolbox.
Agreement enabling customers to access external mRNA capping chemistry for incorporation into production workflows.
Selection of the automated production technology by an external vaccine developer for mRNA vaccine projects.
Adoption of the company's automated midi production system for planned mRNA vaccine production efforts in Latin America.
Public grant awarded to support development of an mRNA manufacturing platform for vaccines and therapeutics.
Research license and supply agreement to provide mRNA formulation technology for personalized cancer therapeutics.
Announcement of a collaboration demonstrating saRNA-based poultry vaccine outcomes using the company's integrated toolbox.
Agreement enabling customers to access external mRNA capping chemistry for incorporation into production workflows.
Selection of the automated production technology by an external vaccine developer for mRNA vaccine projects.
Adoption of the company's automated midi production system for planned mRNA vaccine production efforts in Latin America.
Public grant awarded to support development of an mRNA manufacturing platform for vaccines and therapeutics.